Dasatinib Anhydrous

CHEMBL1421 Phase 4 Aprovado Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

488.0 g/mol

LogP

3.6

Phase

4

The anhydrous crystal form of dasatinib, a BCR-ABL tyrosine kinase inhibitor used for CML and Ph+ ALL. The anhydrous form represents a specific polymorphic crystal structure used in pharmaceutical manufacturing.

Peso Molecular

488,0000 g/mol

LogP

3,60

TPSA

135,00 Å²

Regra dos 5 de Lipinski

Aprovado

Áreas Terapêuticas

Pancreatic Cancer Lymphoma Breast Cancer Prostate Cancer Leukemia

Mecanismo de Ação

Selectively inhibits specific receptor tyrosine kinases involved in tumor cell proliferation, angiogenesis, and survival signaling. By blocking ATP binding to the kinase domain, it prevents phosphorylation cascades that drive cancer cell growth.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mecanismo

Selectively inhibits specific receptor tyrosine kinases involved in tumor cell proliferation, angiogenesis, and survival signaling. By blocking ATP binding to the kinase domain, it prevents phosphorylation cascades that drive cancer …

Estrutura 2D

SVG PNG

Cite this structure

Embed this structure

SMILES

Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1

InChI

InChI=1S/C22H26ClN7O2S/c1-14-4-3-5-16(23)20(14)28-21(32)17-13-24-22(33-17)27-18-12-19(26-15(2)25-18)30-8-6-29(7-9-30)10-11-31/h3-5,12-13,31H,6-11H2,1-2H3,(H,28,32)(H,24,25,26,27)

Molecular Formula

C22H26ClN7O2S

HBD / HBA

3 / 9

Ligações Rotacionáveis

7

Átomos Pesados

33

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Perguntas frequentes

The anhydrous crystal form of dasatinib, a BCR-ABL tyrosine kinase inhibitor used for CML and Ph+ ALL. The anhydrous form represents a specific polymorphic crystal structure used in pharmaceutical manufacturing.

Selectively inhibits specific receptor tyrosine kinases involved in tumor cell proliferation, angiogenesis, and survival signaling. By blocking ATP binding to the kinase domain, it prevents phosphorylation cascades that drive cancer cell growth.

Yes, Dasatinib Anhydrous is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1421. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 3062316. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

PillFYI

Procura informações acessíveis para o paciente?

Dasatinib Anhydrous no PillFYI

Estrutura

Dados Rápidos

Fórmula: C22H26ClN7O2S

Links Externos

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Aviso Médico

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.